Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Switzerland / NCT04300257
Recruiting Observational

Swiss Sarcoma Network: Prediction Model for Patient Selection in Sarcoma Care

NCT04300257 · tracked via the Priya Life Science Switzerland tracker
Phase
Observational
Started
2019-10-19
Last updated
2024-03-20

Condition(s) studied

Sarcoma

Study summary

The primary significance of this project is to perform a detailed analysis to assess the diagnostics, treatment and follow-up care, to develop a prediction model for future patient selection regarding various diagnostic and treatment procedures.

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Malignant and intermediate and selected benign bone or soft tissue tumors, acc. to the WHO coding list of the SSN * Female and male subjects of all ages Exclusion Criteria: * Documented objection of subsequent use of personal health data

Primary outcome measure(s)

Trial sites (8)

FacilityCityRegionStatus
Kantonsspital Winterthur Winterthur Canton of Zurich Recruiting
SwissSarcomaNetwork Winterthur Canton of Zurich Recruiting
Ente Ospedaliero Cantonale Bellinzona Canton Ticino Recruiting
Kantonsspital Graubünden Chur Kanton Graubünden Recruiting
Luzerner Kantonsspital Lucerne Switzerland Recruiting
Pathologie Institut Enge Zurich Switzerland Recruiting
Klinik Hirslanden Zurich Switzerland Recruiting
Stadtspital Zürich Triemli Zurich Switzerland Recruiting

More Kantonsspital Winterthur KSW trials in Switzerland

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04300257 on ClinicalTrials.gov ↗ ← All trials in Switzerland